

DATE:	14 September 2026
TO:	Oncologists, Province Wide
FROM:	Immunohistochemistry Labs, EDM Zone
RE:	Magee Decision Algorithm (MDA): Oncotype DX® Risk Predictor

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective **September 15, 2026**, Breast Cancer surgical pathology reports in Edmonton will begin incorporating the Magee Decision Algorithm (MDA), an Oncotype DX® Risk predictor for a 6-month feasibility pilot prior to formal implementation.

Background

- MDA provides a reliable, cost-effective estimate of whether a patient falls into a Low vs. High recurrence risk category as typically determined by the Oncotype DX® Recurrence Score (RS).
- This initial rollout does not affect current Oncotype DX® ordering pathways. This 6-month pilot allows oncologists to review MDA predictions alongside standard results to build clinical familiarity without impacting existing workflows.
- The launch begins in Edmonton and will expand to North Sector cases. Calgary and the South Sector will follow after completion of the pilot in Phase 2 during Spring 2027 to complete a provincial rollout.

Action Required

- MDA reports are initiated automatically by the lab prior to Oncotype DX® testing. Oncologists maintain their standard workflow and continue to be able to order Oncotype DX® where indicated.

Effective **September 15, 2026**

Questions/Concerns

- Dr. Gilbert Bigras, Medical Lead, Immunohistochemistry, Hub Lab North
Gilbert.bigras@albertaprecisionlabs.ca
- Dr. Chad Luedtke, Provincial Medical Lead, Quality and Business Performance
Chad.luedtke@albertaprecisionlabs.ca

Approved by

- Dr. Michael Mengel, North Sector Medical Director
- Dr. Kate O'Connor, South Sector Medical Director